These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
216 related articles for article (PubMed ID: 34448414)
41. Thyroid-associated ophthalmopathy: Emergence of teprotumumab as a promising medical therapy. Smith TJ Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101383. PubMed ID: 32088116 [TBL] [Abstract][Full Text] [Related]
42. Intraocular pressure improvement in patients receiving teprotumumab for the treatment of thyroid eye disease: a case series. Chu M; Sung J; Song M; Song A; Song J J Med Case Rep; 2022 May; 16(1):195. PubMed ID: 35538553 [TBL] [Abstract][Full Text] [Related]
44. Lessons Learned from Targeting IGF-I Receptor in Thyroid-Associated Ophthalmopathy. Janssen JAMJL; Smith TJ Cells; 2021 Feb; 10(2):. PubMed ID: 33673340 [TBL] [Abstract][Full Text] [Related]
45. Teprotumumab in Clinical Practice: Recommendations and Considerations From the OPTIC Trial Investigators. Douglas RS; Wang Y; Dailey RA; Harris GJ; Wester ST; Schiffman JS; Tang RA; Fowler B; Fleming J; Smith TJ J Neuroophthalmol; 2021 Dec; 41(4):461-468. PubMed ID: 33417417 [TBL] [Abstract][Full Text] [Related]
46. Teprotumumab, an insulin-like growth factor-1 receptor antagonist antibody, in the treatment of active thyroid eye disease: a focus on proptosis. Douglas RS Eye (Lond); 2019 Feb; 33(2):183-190. PubMed ID: 30575804 [TBL] [Abstract][Full Text] [Related]
48. Successful Case of Teprotumumab Treatment in an Adolescent Patient With Thyroid Eye Disease. Radulovich N; Van Brummen A; Chambers C; Zhang M Ophthalmic Plast Reconstr Surg; 2024 Mar-Apr 01; 40(2):e65-e67. PubMed ID: 38231594 [TBL] [Abstract][Full Text] [Related]
49. A Review of Novel Medical Treatments for Thyroid Eye Disease. Park JW; Yoon JS Korean J Ophthalmol; 2024 Jun; 38(3):249-259. PubMed ID: 38773958 [TBL] [Abstract][Full Text] [Related]
50. Irreversible sensorineural hearing loss as a result of azithromycin ototoxicity. A case report. Ress BD; Gross EM Ann Otol Rhinol Laryngol; 2000 Apr; 109(4):435-7. PubMed ID: 10778901 [TBL] [Abstract][Full Text] [Related]
51. Efficacy and Safety of Teprotumumab in Thyroid Eye Disease. Teo HM; Smith TJ; Joseph SS Ther Clin Risk Manag; 2021; 17():1219-1230. PubMed ID: 34858025 [TBL] [Abstract][Full Text] [Related]
52. A Perspective on the Current Role of Teprotumumab in Treatment of Thyroid Eye Disease. Allen RC; Bradley EA; Fante RG; Lucarelli MJ Ophthalmology; 2021 Aug; 128(8):1125-1128. PubMed ID: 33823982 [No Abstract] [Full Text] [Related]
53. A case of rapidly declining glycemic control and diabetic ketoacidosis in a newly diagnosed diabetes patient after starting teprotumumab for thyroid eye disease. Carter C; Marks M; Bundeff AW; Adewodu T; Alderman L Endocrine; 2024 Jan; 83(1):65-68. PubMed ID: 37725291 [TBL] [Abstract][Full Text] [Related]